Novartis development pipeline: AVXS101 in SMA type 1 on track for launch in H1 2019

AVXS101 in SMA type 1 on track for launch in H1 2019, and clinical development underway in all other SMA subtypes Progressing cell, gene and radioligand therapy platforms with 13 therapies in clinical development, and 9 more expected to enter the clinic in 2019. The potentially foundational gene therapy AVXS101… Att fortsätt läsa

AVXS-101: The next gene therapy can trigger a discussion about high costs in SMA TREATMENT

Novartis has now announced the price for gene therapy AVXS-101. Is it expected the cost 4 $ million – 5$ million per patient.

The next expensive treatment will be at some point a contention in our health system. Small countries like Denmark cannot afford the expensive medicine of Spinraza, what is then with this drug!

Although AVXS-101 is given once by single infusion, is the final price entitled!

Tell us what you think about this price. Share your thoughts below 👇

Cure SMA Canada speaks out for the rights of Canadians affected by Spinal Muscular Atrophy to access treatment.

Cure SMA Canada speaks out for the rights of Canadians affected by Spinal Muscular Atrophy to access treatment All patients affected by SMA in Canada have a need and a right to treatment! I say, all patients affected by SMA in worldwide have a right to treatment! #AccessToSpinraza #TillgångTillSpinrazaFörAlla #SpinalMuskelatrofi… Att fortsätt läsa

Safety of intrathecal treatment with nusinersen therapy with SMA

Safety of intrathecal treatment with nusinersen therapy with spinal muscular atrophy SMA Typ 2/3 New study from University Essen shows great results University Essen treated a total of 28 adult SMA patients (9 patients with SMA type 2 and 19 patients with SMA type 3) aged between 18–61 years with nusinersen…. Att fortsätt läsa